AVXL vs SAVA with a higher SP rating from Cantor Fitzgerald for AVXL. Among the SAVA's 3 ratings in the link below, I could not help but notice that Cantor Fitzgerald has a drop target of only $24.00 for SAVA. This is a 52% downside projection for SAVA's share price.
OTOH, Cantor Fitzgerald has a recently raised AVXL's target with a rating of Overweight and set a new price target of $25.00 from $10.00 previously. This is a +92% projected increase in AVXL's share price from Friday's closing of $13.02
So Cantor Fitzgerald has a higher share price target for AVXL over SAVA, interesting indeed since Cantor Fitzgerald knows their stuff when it comes to Biotechs.
I think they recognize how SAVA is a couple of years behind AVXL in Alzheimer's trials, and the fact that 2-73 Blarcamesine works upstream to stop the problem before it forms, whereas SAVA's drug repairs the problem down stream. Making SAVA's drug redundant and not needed. Also Blarcamesine 2-73 does much more to stop Alzheimer's from progressing than SAVA's one trick pony. AVXL has 17 clinical trials listed on their site vs SAVA's one indication. Also SAVA will attempt to enroll 1,600 Alzheimer patients for it's two trials, which will take quite a bit of time to accomplish before the trials can start.
News 
Market Data 
Discover 
